Search - tctmd.com

Displaying 221 - 240 of 306

Sort: Relevancy | Date

SGLT2 Inhibitors in HFrEF and HFpEF

Presentation THT 2022

SGLT2 Inhibitors in HFrEF and HFpEF

Presenter: Stefan Anker

February 01, 2022

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

News Daily News

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

January 26, 2022

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

News Daily News

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

January 21, 2022

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

January 10, 2022

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

December 28, 2021

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

December 07, 2021

SGLT2 inhibitors and Heart Failure

Presentation Controversies and Advances 2021

SGLT2 Inhibitors and Heart Failure

Presenter: Michelle M. Kittleson

December 03, 2021

TCTMD’s Top 10 Most Popular Stories for November 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for November 2021

November 30, 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

November 17, 2021

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

News Conference News

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

November 16, 2021

Canagliflozin Improves Quality of Life in HF Patients

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

November 14, 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

November 08, 2021

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Presentation TCT 2021

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Presenter: Connie Hess

November 06, 2021

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

October 08, 2021

TCTMD’s Top 10 Most Popular Stories for September 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2021

October 01, 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

September 13, 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

News Conference News ESC 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

Yael L. Maxwell

September 03, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.